Prognostic Factors of COVID19 (Covid-HUS)
Study of Clinical, Biological and Genetic Prognostic Factors of SARS-CoV-2 Infection in Patients Admitted in the Strasbourg University Hospitals
COVID-19 is an emerging disease, for which no specific treatment options are currently available. Since the end of February 2020, and due to a SARS-CoV-2 superspreading event (religious meeting), the Strasbourg University Hospital (HUS) had faced a sudden increase of the number of COVID-19-positive patients in serious condition requiring hospitalization. At the same time, many people develop only mild or moderate symptoms. To date, the prognostic factors for the course of SARS-CoV-2 infection are unknown. The primary purpose of the "COVID-HUS" protocol is to investigate viral and host-related factors to understand the pathophysiology of COVID infection and to open the way for new diagnostic, prognostic and therapeutic strategies against SARS CoV-2 .
The secondary objectives are
- Monitoring of viral replication of SARS-CoV-2 in the blood and respiratory tract in infected patients
- Monitoring of the humoral and cellular response directed against SARS-CoV-2
- Identification of factors leading to significant and / or prolonged viral replication of SARS-CoV-2 in the blood or respiratory samples
- Evaluation of the benefit of possible treatments implemented following the diagnosis of SARS-CoV-2 infection
- Exploration of the B and T immune repertoire sequences targeting SARS-CoV-2 in infected patients
- Typing of the HLA system in infected patients
研究概览
地位
条件
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
-
Strasbourg、法国、67091
- 招聘中
- Service de Virologie - Hôpital Civil
-
副研究员：
- Yvon Ruch, MD
-
接触：
- Samira FAFI-KREMER, PharmD, PhD
- 电话号码：33.3.69.55.14.38
- 邮箱：Samira.fafi-kremer@chru-strasbourg.fr
-
首席研究员：
- Samira FAFI-KREMER, PharmD, PhD
-
副研究员：
- Floriane GALLAIS, MD
-
副研究员：
- Ilies BENOTMANE, MD
-
副研究员：
- Héloïse DELAGREVERIE, MD
-
副研究员：
- Morgane SOLIS, MD
-
副研究员：
- Eric SOULIER, InG
-
副研究员：
- François Danion, MD
-
副研究员：
- Aurélie VELAY, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Adult and pediatric with suspicion or a confirmed SARS-CoV-2 infection
- Patient who has signed a non-opposition form (or a form signed by a family member or a support person if the seriousness of the patient's condition and the emergency situation do not allow it) or who has given his oral agreement to the doctor
Exclusion Criteria:
- Patient's explicit refusal to participate
- Subject deprived of liberty or subject to the protection of justice
- Subject under guardianship or trusteeship
学习计划
研究是如何设计的？
设计细节
- 观测模型：仅案例
- 时间观点：其他
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Clinical Presentation and Incidence of Covid-19 Infection in patients hospitalised in Strasbourg Hospital
大体时间：From 1st March 2020 to 1st March 2021
|
From 1st March 2020 to 1st March 2021
|
合作者和调查者
调查人员
- 研究主任：Samira FAFI-KREMER, PharmD, PhD、Laboratoire de Virologie Plateau Technique de Microbiologie
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 7760
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.